Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20691951 | 0.72 | SLC29A1 (0.37) | — | |
| SCHEMBL20691367 | 0.71 | SLC29A1 (0.51) | — | |
| SCHEMBL24060657 | 0.70 | SLC29A1 (0.32) | — | |
| SCHEMBL22349184 | 0.69 | SLC29A1 (0.47) | — | |
| SCHEMBL25688810 | 0.66 | SLC29A1 (0.45) | — | |
| SCHEMBL20692234 | 0.65 | CNR2 (0.32) | — | |
| SCHEMBL14156818 | 0.65 | PNP (0.60) | — | |
| SCHEMBL24680745 | 0.64 | SLC29A1 (0.32) | — | |
| SCHEMBL22577618 | 0.63 | SLC29A1 (0.61) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL14156813 | 0.63 | PIM1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | POLA1 48/4885ADORA2A 1110/4885ADORA2B 1818/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | POLA1 48/4885ADORA2A 1110/4885ADORA2B 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.